Cancer specialists not involved in the new research expressed optimism that this may be a turning point in the quest for new ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited—and time matters. As the disease progresses, the window for effective, less ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less ...

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality. Researchers at Rice University, in collaboration ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...